Sisram Medical Ltd has announced a continuing connected transaction through a Supply Framework Agreement, effective June 10, 2025, between Sisram HK and Sisram Tianjin. Under this agreement, Sisram HK will supply the Product, botulinum toxin type A for injection, known by the trademark DAXXIFY® in English, to Fosun Wanbang (Jiangsu). The product is indicated for the temporary improvement of moderate to severe glabellar lines in adult patients. This agreement reflects Sisram Medical's ongoing efforts to expand its market presence and strengthen its partnership with Fosun Wanbang, a subsidiary of Fosun Pharma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.